8-K current report · filed Sep 14, 2026

Definium Therapeutics, Inc. (DFTX) 8-K Current Report: September 14, 2026

Item 8.01Item EX-99.1Item EX-99.2Item 7.01DFTX overview

Short answer

Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Positive topline Phase 3 Panorama data for DT120 ODT in generalized anxiety disorder.

Definium Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Positive topline Phase 3 Panorama data for DT120 ODT in generalized anxiety disorder
  • Clinical update marks a potentially important development for Definium’s lead therapeutic program
  • Full efficacy and safety results available in Exhibit 99.1 fodder for assessing regulatory and commercial prospects

Item 8.01 · Other Events

  • Presentation announces Panorama topline data, a potentially material clinical-development update
  • Investors should review Exhibit 99.2 for efficacy, safety, endpoint and trial-result details
  • Publication on September 14, 2026 may inform DFTX’s regulatory and commercialization outlook

Item EX-99.1 · Exhibit EX-99.1

  • Panorama met primary and all key secondary endpoints in 245-patient Phase 3 GAD trial, reinforcing DT120 ODT’s regulatory case
  • HAM-A placebo-adjusted improvement reached 5.1 points at Week 12, with p<0.0001 and Cohen’s d=0.64
  • 100 µg dose showed 94.8% TEAE rate, but no drug-related serious adverse events and 10.4% discontinuation
  • Pre-NDA meeting planned for 4Q 2026, with NDA filing anticipated in 1H 2027
  • Development risk remains around FDA review and controlled-substance scheduling before potential commercialization

Item EX-99.2 · Exhibit EX-99.2

  • Phase 3 Panorama met all primary and key secondary endpoints in GAD, strengthening DT120 ODT’s path toward regulatory filing
  • DT120 ODT 100 µg improved HAM-A versus placebo by 5.1 points at week 12 and 5.3 points at week 1, both p<0.0001
  • Response, remission, and mild-or-better rates reached 32%, 15%, and 35% versus 14%, 4%, and 17% for placebo
  • Safety profile showed no suicidality signal, no drug-related serious adverse events, and no discontinuations, though any treatment-emergent event occurred in 95%
  • Operational profile supports commercialization: average session clearance 6.2 hours and 94% cleared by 8 hours in Panorama

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Definium Therapeutics, Inc. 8-K filings

Get the next DFTX 8-K as it lands

Follow DFTX for push alerts, or ask the research agent what this filing means.